Repurposing the diuretic benzamil as an anti-osteosarcoma agent that acts by suppressing integrin/FAK/STAT3 signalling and compromising mitochondrial function.
Meng-Chieh LinGuan-Yu ChenHsin-Hsien YuPei-Ling HsuChu-Wan LeeChih-Cheng ChengShih-Ying WuBo-Syong PanBor-Chyuan SuPublished in: Bone & joint research (2024)
Benzamil exerts anti-osteosarcoma activity by inducing apoptosis. In terms of mechanism, benzamil appears to inhibit integrin/FAK/STAT3 signalling, which triggers mitochondrial dysfunction and ATP depletion.